The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin
Abstract
Defective axonal transport has been proposed as an underlying mechanism that may give rise to neurodegeneration. We investigated the effect of phosphorylation on the axonal transport of tau, a neuronal protein that stabilizes microtubules and is hyperphos‐phorylated and mislocalized in Alzheimer's disease. We report here that specific inhibition of glycogen synthase kinase‐3 (GSK‐3) reduces tau phosphorylation and significantly decreases the overall rate of axonal transport of tau in rat cortical neurons. Tau mutants, with serine/ threonine targets of GSK‐3 mutated to glutamate to mimic a permanent state of phosphorylation, were transported at a significantly increased rate compared to wild‐type tau. Conversely, tau mutants, in which alanine replaced serine/threonine to mimic permanent dephosphorylation, were transported at a decreased rate compared to wild‐type tau. We also found that tau interacts with the light chain of kinesin‐1 and that this is dependent on the phosphorylation state of tau. Tau phosphorylation by GSK‐3 increased binding, and de‐phosphorylated tau exhibited a reduced association with kinesin‐1. We conclude that GSK‐3 phosphorylation of tau modulates its axonal transport by regulating binding to kinesin‐1. Hyperphosphorylated tau in Alzheimer's disease appearing first in distal portions of axons may result from aberrant axonal transport of phosphorylated tau reported here.—Cuchillo‐Ibanez, I., Seereeram, A., Byers, H. L., Leung, K.‐Y., Ward, M. A., Anderton, B. H., Hanger, D. P. Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J. 22, 3186–3195 (2008)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J.-P., & Anderton, B. H. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90774-2 · Cited by 737
Self-citationKamal, A., Stokin, G. B., Yang, Z., Xia, C.-H., & Goldstein, L. S. B. (2000) · Neuron · doi:10.1016/s0896-6273(00)00124-0 · Cited by 544
Pei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199909000-00011 · Cited by 459
Hanger, D. P., Byers, H. L., Wray, S., Leung, K.-Y., Saxton, M. J., Seereeram, A., Reynolds, C. H., Ward, M. A., & Anderton, B. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703269200 · Cited by 455
Self-citationThe Roles of Cyclin-dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation
Plattner, F., Angelo, M., & Giese, K. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603469200 · Cited by 340 · cited 1×
“Alternatively, because cdk5 has been shown to phosphorylate GSK-3, with the result that GSK-3 is less active (56), the report that cdk5 reduced tau transport rate would be consistent with our finding if the mechanism was via GSK-3 inhibition.”
ResultWilliams, D. R. (2006) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01153.x · Cited by 259 · cited 1×
“Aberrant forms of tau are implicated in the pathogenesis of several neurodegenerative diseases in which tau deposits are found, and these are collectively termed tauopathies (1).”
BackgroundAxonal transport, tau protein, and neurodegeneration in Alzheimer's disease
Terwel, D., Dewachter, I., & Van Leuven, F. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:2:151 · Cited by 146 · cited 1×
“Taken together with our data, these results may account for the observation that tangle pathology in Alzheimer’s disease appears to commence distally and then spreads in a retrograde fashion to the perikaryon (58, 59).”
Cited by
The role of tau in neurodegeneration
Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478
The importance of tau phosphorylation for neurodegenerative diseases
Noble, W., Hanger, D. P., Miller, C. C. J., & Lovestone, S. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00083 · Cited by 475
Self-citationStructure and Pathology of Tau Protein in Alzheimer Disease
Kolarova, M., García-Sierra, F., Bartos, A., Ricny, J., & Ripova, D. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/731526 · Cited by 468
Jung, T., Catalgol, B., & Grune, T. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.04.001 · Cited by 389
Alavi Naini, S. M., & Soussi-Yanicostas, N. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/151979 · Cited by 316
GSK-3 and tau: a key duet in Alzheimer’s disease
Sayas, C. L., & Ávila, J. (2021) · Cells · doi:10.3390/cells10040721 · Cited by 314
“Tau axonal transport relies on its interaction with kinesin-1, which is dependent on GSK-3 phosphorylation [112].”
BackgroundA role for tau at the synapse in Alzheimer’s disease pathogenesis
Pooler, A. M., Noble, W., & Hanger, D. P. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.09.018 · Cited by 203
“Changes in tau phosphorylation also affect transport of tau in neurons (Cuchillo-Ibanez et al., 2008; Rodriguez-Martin et al., 2013).”
BackgroundSelf-citationGSK‐3 in Neurodegenerative Diseases
Lei, P., Ayton, S., Bush, A. I., & Adlard, P. A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/189246 · Cited by 177
“GSK-3β has been found to be associated with normal microtubule-bound tau [37] as well as with the hyperphosphorylated tau deposits in the AD brain [38, 39].”
BackgroundDynamic association of tau with neuronal membranes is regulated by phosphorylation
Pooler, A. M., Usardi, A., Evans, C. J., Philpott, K. L., Noble, W., & Hanger, D. P. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.01.005 · Cited by 148
Self-citationTau protein diffuses along the microtubule lattice
Hinrichs, M. H., Jalal, A., Brenner, B., Mandelkow, E., Kumar, S., & Scholz, T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.369785 · Cited by 141
Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion
Ahmed, T., Van der Jeugd, A., Blum, D., Galas, M.-C., D’Hooge, R., Buee, L., & Balschun, D. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.05.005 · Cited by 137
Connecting the dots between tau dysfunction and neurodegeneration
Frost, B., Götz, J., & Feany, M. B. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.07.005 · Cited by 124
Ambegaokar, S. S., & Jackson, G. R. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr432 · Cited by 113
Mediators of tau phosphorylation in the pathogenesis of Alzheimer’s disease
Hanger, D. P., Seereeram, A., & Noble, W. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.104 · Cited by 98
Self-citationThe toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics
Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89
“Inhibition of anterograde axonal transport is now thought to be associated with the ability of tau to bind kinesin [109, 110].”
BackgroundCerebrospinal fluid lactate is associated with multiple sclerosis disease progression
Albanese, M., Zagaglia, S., Landi, D., Boffa, L., Nicoletti, C. G., Marciani, M. G., Mandolesi, G., Marfia, G. A., Buttari, F., Mori, F., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0502-1 · Cited by 88
The Pathophysiology of Axonal Transport in Alzheimer's Disease
Vicario-Orri, E., Opazo, C. M., & Muñoz, F. J. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-141080 · Cited by 41
Tau; One Protein, So Many Diseases
Tabeshmehr, P., & Eftekharpour, E. (2023) · Biology · doi:10.3390/biology12020244 · Cited by 33
Watamura, N., Toba, J., Yoshii, A., Nikkuni, M., & Ohshima, T. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23674 · Cited by 25
Metadata
- Authors
- Cuchillo‐Ibanez, I., Seereeram, A., Byers, H. L., Leung, K., Ward, M. A., Anderton, B. H., & Hanger, D. P.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2008-05-29
- Volume
- 22
- Issue
- 9
- Pages
- 3186-3195
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2169200799
- Cited by
- 170
- References
- 8
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.